Effect of monophosphoryl lipid A on antibody response to diphtheria toxin and its subunits

APMIS

Volumn 113, Issue 4, 2005, Pages 256-263

  Caglar, Kayhan ^a   Aybay, Cemalettin ^a   Ataoglu, Haluk ^b  

^a GAZI UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Diphtheria toxin; Fragment A; Fragment B; Monophosphoryl lipid A

Indexed keywords

DIPHTHERIA TOXIN; DIPHTHERIA TOXIN A; DIPHTHERIA TOXIN B; DIPHTHERIA TOXOID; DIPHTHERIA VACCINE; IMMUNOLOGICAL ADJUVANT; PHOSPHORYL LIPID A; PROTEIN SUBUNIT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; IMMUNIZATION; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; DIPHTHERIA; DIPHTHERIA TOXIN; DIPHTHERIA TOXOID; DRUG EVALUATION, PRECLINICAL; FEMALE; IMMUNIZATION; INJECTIONS, SUBCUTANEOUS; LIPID A; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS;

EID: 18744365165     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2005.apm_03.x     Document Type: Article

References (37)

1. Galazka AM, Robertson SE, Oblapenko GP. Resurgence of diphtheria. Eur J Epidemiol 1995;11:95-105.
2. Vitek CR, Wharton M. Diphtheria in the former Soviet Union: reemergence of a pandemic disease. Emerg Infect Dis 1998;4:539-50.
3. Kadirova R, Kartoglu HU, Strebel PM. Clinical characteristics and management of 676 hospitalized diphtheria cases, Kyrgyz Republic. J Infect Dis 1995;181:S110-5.
4. Eidels L, Proia RL, Hart DA. Membrane receptors for bacterial toxins. Microbiol Rev 1983;47:596-620.
5. Cieplak W, Hasemann C, Eidels L. Specific cleavage of diphtheria toxin by human urokinase. Biochem Biophys Res Commun 1988;157:747-54.
6. Zucker DR, Murphy JR. Monoclonal antibody analysis of diphtheria toxin-I. Localization of epitopes and neutralization of cytotoxicity. Mol Immunol 1984;21:785-93.
7. Von Hunolstein C, Rota MC, Alfarone G, Ricci ML, Salmaso S. Diphtheria antibody levels in the Italian population. Eur J Clin Microbiol Infect Dis 2000;19:433-7.
8. Nicolay U, Girgsdies OE, Banzhoff A, Hundt E, Jilg W. Diphtheria booster vaccination: one or two injections? Vaccine 1999;17:2223-8.
9. de Melker HE, Berbers GAM, Nagelkerke NJ, Conyn-van Spaendonck MA. Diphtheria anti-toxin levels in the Netherlands: a population-based study. Emerg Infect Dis 1999;5:694-700.
10. Qureshi N, Takayama K, Ribi E. Purification and structural determination of nontoxic lipid A obtained from lipopolysaccharide of Salmonella typhimurium. J Biol Chem 1982;257:11808-15.
11. Ribi E. Beneficial modification of the endotoxin molecule. J Biol Response Mod 1984;3:1-9.
12. Baldridge JR, Yorgensen Y, Ward JR, Ulrich JT. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 2000;18:2416-25.
13. Thompson HS, Davies ML, Watts MJ, Mann AE, Holding FP, O'Neill T, et al. Enhanced immunogenicity of a recombinant genital warts vaccine adjuvanted with monophosphoryl lipid A. Vaccine 1998;16:1993-9.
14. Lodmell DL, Ray NB, Ulrich JT, Ewalt LC. DNA vaccination of mice against rabies virus: effects of the route of vaccination and the adjuvant monophosphoryl lipid A (MPL®). Vaccine 2000;18:1059-66.
15. Neuzil KM, Johnson JE, Tang YW, Prieels JP Slaoui M, Gar N, et al. Adjuvants influence the quantitative and qualitative immune response in BALB/c mice imunized with respiratory syncytial virus FG subunit vaccine. Vaccine 1997;15:525-32.
16. Thoelen S, Van Damme P, Mathei C, Leroux-Roels G, Desombere I, Safary A, et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 1998;16:708-14.
17. Ambrosch F, Wiedermann G, Kungi M, Leroux-Roels G, Desombere I, Garcon N, et al. A hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 2000;18:2095-101.
18. Thoelen S, deClercq N, Tornieporth N. A prophylactic hepatitis B vaccine with a novel adjuvant system. Vaccine 2001;19:2400-03.
19. Baldridge JR, Crane RT. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods 1999;19:103-7.
20. Drazin R, Kandel J, Collier RJ. Structure and activity of diphtheria toxin. J Biol Chem 1971;246:1504-10.
21. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
22. Wörner W. Conjugating peroxidase. In: Peters JH, Baumgarten H, editors. Monoclonal Antibodies. Berlin: Springer-Verlag, 1992:294-6.
23. RJ Collier. Diphtheria toxin: mode of action and structure. Bacteriol Rev 1975;39:54-85.
24. Kristiansen M, Aggerbeck H, Heron I. Improved ELISA for determination of anti-diphtheria and/ or anti-tetanus antitoxin antibodies in sera. APMIS 1997;105:843-53.
25. Dular U. Comparative studies of the in vivo toxin neutralization and the in vitro vero cell assay methods for use in potency testing of diphtheria component in combined vaccines/toxoids. Biologicals 1993;21:53-9.
26. Isaka M, Yasuda Y, Mizokami M, Kozuka S, Taniguchi T, Matano K, et al. Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholerae toxin B subunit adjuvant. Vaccine 2001;19:1460-6.
27. Hoffman S, Edelman R, Bryan JP, Schneider I, Davis J, Sedegah M, et al. Safety, immunogenicity. and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant. Am J Trop Med Hyg 1994;51:603-12.
28. Isaka M, Yasuda Y, Kozuka S, Miura Y, Taniguchi T, Matano K, et al. Systemic and mucosal immune responses of mice to aluminium-adsorbed and aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit. Vaccine 1998;16:1620-6.
29. Walory J, Grzesiowski P, Hryniewicz W. Comparison of four serological methods for the detection of diphtheria anti-toxin antibody. J Immunol Methods 2000;245:55-65.
30. Aggerbeck H, Heron I. Improvement of a vero cell assay to determine diphtheria antitoxin content in sera. Biologicals 1991;19:71-6.
31. Kreeftenberg JG, van der Gun J, Marsman FR, Sekhuis VM, Bhandari SK, Maheshwari SC. An investigation of a mouse model to estimate the potency of the diphtheria component in vaccines. J Biol Stand 1985;13:229-34.
32. Melville-Smith M, Balfour A. Estimation of Corynebacterium diphtheria antitoxin in human sera: a comparison of an enzyme-linked immunosorbant assay with toxin neutralisation test. J Med Microbiol 1988;25:279-83.
33. Lau RC. Detection of diphtheria toxin antibodies in human sera in New Zealand by ELISA. J Hyg (Lond) 1986;96:415-8.
34. Gizurarson S, Sigurdoardottir M, Stanzeit B. Selective augmentation of antibodies in various mucosal regions, after intranasal immunization with diphtheria in mice. J Pharm Sci 1988;87:1267-9.
35. Isaka M, Yasuda Y, Kozuka S, Taniguchi T, Matano K, Maeyama J, et al. Induction of systemic and mucosal antibody response in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant. Vaccine 1999;18:743-51.
36. Perera VY, Corbel MJ. Human antibody response to fragments A and B of diphtheria toxin and a synthetic peptide of amino acid residues 141-157 of fragment A. Epidemiol Infect 1990;105:457-68.
37. Triebel F, Autran B, De Roquefeuil S, Falmagne P, Debre P. Immune response to diphtheria toxin and to different CNBr fragments: evidence for different B and T cell reactivities. Eur J Immunol 1986;16:47-53.